Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

OmniAb (OABI) Long-Term Debt Issuances (2021 - 2022)

OmniAb (OABI) reported Long-Term Debt Issuances of $250000.0 for Q2 2022, down 50.0% on a QoQ basis from $500000.0 in Q1 2022.

OmniAb (OABI) has 2 years of Long-Term Debt Issuances data on file, last reported at $250000.0 in Q2 2022.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to $250000.0 in Q2 2022, while the trailing twelve-month figure through Sep 2022 was $805725.0 (changed N/A YoY) and the FY2021 annual result came in at $175000.0, changed N/A from the prior year.
  • Long-Term Debt Issuances fell to $250000.0 in Q2 2022 per OABI's latest filing, from $500000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $500000.0 in Q1 2022 and bottomed at $55725.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 OmniAb 334.72 Mn 291.75 Mn 14.41 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 250,000.00
Jun 30, 2022 250,000.00
Mar 31, 2022 500,000.00
Mar 31, 2022 500,000.00
Dec 31, 2021 55,725.00
Dec 31, 2021 55,725.00